More employers using incentives
June 30th 2008The number of major employers offering employee wellness programs with incentives grew over the past year, according to a study presented by Health2 Resources. The National Association of Manufacturers and The ERISA Industry Committee participated in the survey.
Read More
Lack of access can be life-changing
June 30th 2008Access to coverage, especially for individuals and small groups, is a constant issue. So much so that many Americans are taking great steps to change their lifestyles in order to obtain it. Get married to gain access to insurance? Some are doing just that.
Read More
Government proposal could allow e-Rx of controlled substances
June 30th 2008U.S. drug regulators are said to be close to allowing doctors to e-prescribe addictive medications, including painkillers. According to Reuters, the Drug Enforcement Administration is expected to publish a proposal on e-prescribing controlled substances.
Read More
Two votes determine Medicare payment rule
June 30th 2008Two votes from Republican senators killed a House bill that would have averted statutory payment reductions for Medicare physicians, just before legislators left Capitol Hill for their Independence Day holiday. Medicare physicians now face 10.6% fee cuts, but there is an opportunity for retrospective increases after the recess.
Read More
Human factors make or break continuous glucose monitoring
June 7th 2008Real-time continuous glucose monitoring (CGM) can significantly improve glycemic control, but it will not help all patients. "Real-time CGM will add significantly to glucose management for some people, but not for all," said Irl Hirsch, MD, University of Washington, Seattle. "Human factors make all the difference between success and failure. Some patients will never figure it out. That?s why real-time control is so challenging.
Read More
Pharmacologic options for painful diabetic neuropathy reviewed
June 7th 2008Good glycemic control is not sufficient to relieve painful diabetic neuropathy, necessitating investigation of other modalities to achieve analgesic efficacy. Dan Ziegler, MD, German Diabetes Clinic, German Diabetes Center, and professor of internal medicine, Leibniz Institute at the Heinrich Heine University, Düsseldorf, provided an overview of pharmacologic treatments that have been explored for painful diabetic neuropathy and the success achieved with each.
Read More
Reformers seek more comparative effectiveness information to control healthcare spending
June 5th 2008Healthcare reform is a high-profile issue in the presidential election campaign, and drug access has become a central theme in the debate. Both Democratic and Republican candidates have rolled out healthcare reform plans that promise to cover the uninsured while also providing tax breaks and other incentives to help individuals obtain health insurance.
Read More
Prophylactic anticoagulation guidelines developed specifically for patients with cancer
June 2nd 2008Ambulatory patients with cancer who are undergoing chemotherapy should not receive prophylactic anticoagulation to prevent venous thromboembolism, according to new guidelines developed by ASCO. "It's not cost effective and we also do not recommend screening these patients for thrombophilia," said Mark Levine, MD, McMaster University, Hamilton, Ontario, Canada.
Read More
Paroxetine ineffective for insomnia treatment in patients with cancer
June 2nd 2008Physicians treating cancer-related depression with paroxetine should not expect patients' insomnia to also improve, according to a study presented by Oxana G. Palesh, PhD, University of Rochester Cancer Center, NY. "We know that insomnia and depression often occur together frequently in the general population, suggesting that there may be a common mechanism," she said.
Read More
Clinicians too cautious in use of chemotherapy for oldest patients with stage III colon cancer
June 2nd 2008Advanced age should not be a barrier to initiating adjuvant chemotherapy in patients with stage III colon cancer. In an observational study, the oldest patients suffered no more adverse events when treated with adjuvant chemotherapy than did younger patients but were much less likely than their younger counterparts to actually receive adjuvant chemotherapy for their colon cancer, said Katherine L. Khan, MD, professor of medicine at the University of California, Los Angeles.
Read More
Fatigue affects broad range of activities among patients with cancer
June 2nd 2008Cancer-related fatigue significantly interferes with patients' quality of life, and some areas often affected among these patients are not normally included on standard quality-of-life assessments, said Karen M. Mustian, PhD, University of Rochester School of Medicine, NY. More randomized, controlled trials are needed to identify these areas, she said.
Read More
MRI added to mammography identifies most ductal components of invasive breast cancer
June 2nd 2008Magnetic resonance imaging (MRI) is superior to mammography alone in diagnosing intraductal components of invasive breast cancer, allowing more accurate mapping before breast conservation surgery, said Simone Schrading, MD, Department of Radiology, University of Bonn, Germany.
Read More
Aerobic and strength exercise program improves several variables during chemotherapy treatment
June 2nd 2008An individualized exercise program may significantly reduce fatigue, increase strength, and improve psychosocial functioning during cancer treatment, according to results of a small study reported by Maike de Wit, University Clinic Hamburg, Germany.
Read More
Blood assay may detect early lung cancer
June 1st 2008An RNA signature present in blood that is highly accurate for detecting prevalent lung cancer can accurately predict the development of lung cancer within the next 2 years 80% of the time, said Thomas Zander, MD, Department of Internal Medicine and the Center for Integrated Oncology, University Clinic Cologne, Germany. "Early detection of lung cancer is a major need, as most patients present for diagnosis at a late stage when there is no chance for cure," Dr Zander said. Two-year survival after a lung cancer diagnosis is approximately 15%. Early detection may therefore be a promising strategy to improve survival rates.
Read More
Acupuncture demonstrates promise in treating symptoms after neck dissection
June 1st 2008A small study suggests that acupuncture has the potential to reduce pain and dysfunction in patients with head and neck cancer who have undergone neck dissection, said David G. Pfister, MD, chief, Head and Neck Medical Oncology, Memorial Sloan Kettering Cancer Center, New York.
Read More
High-dose vitamin D relieves pain and fatigue associated with aromatase inhibitor therapy
June 1st 2008High-dose vitamin D supplementation can provide relief of symptoms related to vitamin D deficiency from aromatase inhibitor therapy in postmenopausal women with breast cancer, said Q.J. Khan, MD, Cancer Center of Kansas, Wichita.
Read More
Combined treatment benefits elderly patients with lung cancer
June 1st 2008Most elderly patients do not receive combined modality treatment (CMT) with both chemotherapy and radiation for locally advanced, non-small cell lung cancer (NSCLC) despite trial data indicating that CMT enhances survival, decreases comorbidities, and is potentially curative. Data presented by Martin J. Edelman, MD, professor of medicine, University of Maryland Greenebaum Cancer Center, Baltimore, indicate that elderly patients receiving chemotherapy followed by concurrent chemotherapy and radiation derive the most significant survival benefit.
Read More
Use of ESAs should be restricted to indications, experts say
June 1st 2008Strict evidence-based criteria should be used when prescribing erythropoiesis-stimulating agents (ESAs) for cancer, as ESAs appear to activate signaling pathways that are important in altering tumor behavior and treatment response, experts said.
Read More
Experts discuss rules for access to experimental drugs
June 1st 2008The extent to which patients should have access to experimental therapies is a hotly contested issue, and courts and regulatory agencies have wrestled with the problems involved when an individual is willing to be treated with unapproved drugs at the potential expense of causing harm not only to the individual but to the clinical trial process itself.
Read More
KRAS gene status predicts response to initial biologic treatment for colorectal cancer
June 1st 2008Patients with metastatic colorectal cancer are more likely to respond to initial treatment that includes cetuximab if they have nonmutated, wild-type KRAS gene status, reported Eric Van Cutsem, MD, University Hospital Gasthuisberg, Leuven, Belgium. "For the first time in colorectal cancer, we are able to predict which patients are likely to be helped by the new biologics," he said. "KRAS is the first molecular marker for the selection of a targeted therapy in combination with a standard chemotherapy regimen in first-line metastatic colorectal cancer. KRAS testing should be routinely conducted in all colorectal cancer patients immediately after diagnosis to ensure the best treatment strategies for the individual patient."
Read More
Electronic medication management system available to improve medication adherence
June 1st 2008In June 2007, FDA approved an Electronic Medication Management Assistant (EMMA) device and electronic medication administration record (eMAR) to help combat problems involving drug identification and dosing.
Read More
Glatiramer, interferon beta-1b comparable in early RRMS
June 1st 2008An investigational 500-mcg dose of interferon beta-1b demonstrated no advantage compared with the approved 250-mcg dose of interferon beta-1b or with glatiramer 20 mg in reducing relapse risk in patients with early relapsing-remitting multiple sclerosis (RRMS), said Paul O'Connor, MD, MS Program Director, St. Michael's Hospital, the University of Toronto, at the 60th Annual Meeting of the American Academy of Neurology, Chicago.
Read More
Glatiramer effective in delaying clinical MS
June 1st 2008Glatiramer represents a new option for delaying conversion of clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (CDMS), according to the results of a new study known as PRECISE, presented at the 60th Annual Meeting of the American Academy of Neurology, Chicago.
Read More